Global Hepatitis Drugs Industry Overview | By Viruses Type (Hepatitis A, Hepatitis B, Hepatitis C, Hepatitis D, and Hepatitis E), By Drugs Type (Oral, Injunction) - Global Industry Opportunity and Current Growth Analysis 2019-2025


Global Hepatitis Drugs Industry was valued at USD 99 Billion in the year 2019. Global Hepatitis Drugs Industry is further estimated to grow at a CAGR of 15.3% from 2019 to reach USD 240 Billion by the year 2025. Hepatitis is where the liver is prevalently influenced, which can likewise influence the stomach related framework and cerebrum. There are three types of hepatitis condition – HAV, HBV, and HCV. HCV is a noteworthy public health issue that assaults the liver and prompts inflammation. Certain drugs, toxins, bacterial and viral infections, and heavy alcohol use can cause hepatitis infection. Hepatitis C contamination can bring both intense and incessant hepatitis infection. Roughly, 80% of the patients get incessantly contaminated with Hepatitis C ailment. Hepatitis C Virus (HCV) spreads through the blood of a contaminated individual by the utilization of shared needles or supplies used to implant drugs. Antibodies are accessible just for Hepatitis An and Hepatitis B infections. Investigation into the advancement of an immunization for Hepatitis C is in progress.


The real drivers of the hepatitis drugs industry incorporate the second era DAAs of Olysio and Sovaldi. Second era DAAs are progressively adequate and have lesser unfavorable impacts. As of now, the market players are creating IFN treatments for the treatment of Hepatitis C. These treatments are planned to be all-oral regimens. The HCV drugs section included over 84% of the absolute piece of the overall industry in 2016. A noteworthy concentration in this portion is required to drive the development of the hepatitis drugs industry later on.


Major market players in Hepatitis Drugs Industry are F. Hoffmann-La Roche Ltd., Gilead Sciences Inc., Vertex Pharmaceuticals Inc., Merck & Co. Inc., Johnson & Johnson, Novartis AG, GlaxoSmithKline PLC, Mitsubishi Tanabe Pharma Corporation, AbbVie Inc., Dynavax Technologies Corporation, and Bristol-Myers Squibb Company


Hepatitis Drugs Industry Segmentation:

Hepatitis Drugs Industry Overview, By Viruses Type

  • Hepatitis A
  • Hepatitis B
  • Hepatitis C
  • Hepatitis D
  • Hepatitis E


Hepatitis Drugs Industry Overview, By Drugs Type

  • Oral
  • Injection


Hepatitis Drugs Industry Overview, By Region

North America


• Canada


• Germany

• U.K.

• France

• Italy

• Rest of Europe


• China

• India

• Japan

• Rest of Asia-Pacific


• Latin America

• Middle East & Africa

License Type

Find About Us

Contact Us

USA Address

7309 Woodward Ave, Apt 107, Woodridge, Illinois, USA, 60517

Operational & Marketing Center

Global Reports Store Pune (India) Manjari(bk), Hadapsar, Pune 412307


Copyright © 2020 Global Reports Store All rights reserved.